Showing 2011-2020 of 2658 results for "".
- Nanoscope Therapeutics Names Glenn Sblendorio as Chairman of the Boardhttps://modernod.com/news/nanoscope-therapeutics-names-glenn-sblendorio-as-chairman-of-the-board/2481994/Nanoscope Therapeutics announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. In a news release, Nanoscope said Mr. Sblendorio's comprehensive understanding of finance and business development will assist in guiding N
- Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-patients-with-lca1/2481991/Atsena Therapeutics announced positive 12-month safety and efficacy data from the ongoing phase 1/2 trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 ha
- Ocuphire Pharma Appoints Joseph K. Schachle COOhttps://modernod.com/news/ocuphire-pharma-reports-inducement-grant-for-new-coo/2481985/Ocuphire Pharma announced that the independent members of its Board of Directors approved an equity award under the company’s 2021 Inducement Plan as a material inducement to Joseph K. Schachle in connection with his employment with Ocuphire effective on November 27, 2023. The equity award
- Skye Bioscience Begins Phase 2 Study of SBI-100 Ophthalmic Emulsion to Treat Glaucomahttps://modernod.com/news/skye-bioscience-begins-phase-2-study-of-sbi-100-ophthalmic-emulsion-to-treat-glaucoma/2481984/Skye Bioscience, which is developing drugs targeting the endocannabinoid system and focusing on glaucoma and metabolic conditions, announced it has treated the first patient in its phase 2 clinical trial evaluating SBI-100 ophthalmic emulsion’s ability to lower IOP as well as safe
- NEI Director Highlights Metabolomics as an Approach to Understanding Glaucomahttps://modernod.com/news/nei-director-highlights-metabolomics-as-an-approach-to-understanding-glaucoma/2481982/The National Eye Institute (NEI) announced that NEI Director Michael F. Chiang, MD, featured recent research by NEI grantee Louis Pasquale, MD, in a National Institute of Health Director’s Blog post. Dr. Pasquale in collaboration with Jae Hee Kang, ScD, and Oana Zeleznik, PhD, explored 369
- Emily Chew, MD, Named NIH Distinguished Investigatorhttps://modernod.com/news/emily-chew-md-named-nih-distinguished-investigator/2481980/Emily, Chew, MD, has been promoted to the title of NIH Distinguished Investigator for her work as a care provider and clinical trialist. Dr. Chew directs National Eye Institute's Division of Epidemiology and Clinical Applications (DECA). An ophthalmologist, she specializes in c
- Genentech and Nvidia Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Developmenthttps://modernod.com/news/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/2481979/In a move aimed at speeding up drug discovery and development, Genentech announced a multi-year strategic research collaboration with Nvidia. Financial terms of the deal were not disclosed. The partnership will combine Genentech’s artificial intelligence
- Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-to-enter-clinic-with-treatment-for-dry-amd/2481974/Inflammasome Therapeutics, developer of a new class of inflammasome inhibitor drugs called Kamuvudines, announced the FDA has granted approval for the opening of a phase 1/2 clinical trial of the company’s drug for the treatment of geographic atrophy (GA). This is the first clinical tr
- EyeBio Announces Expansion of Series A to $130 Million to Advance Development of Restoret for Retinal Diseaseshttps://modernod.com/news/eyebio-announces-expansion-of-series-a-to-130-million-to-advance-development-of-restoret-for-retinal-diseases/2481969/Eyebiotech announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million. EyeBio will use the proceeds from the funding to accelerate the company’s clinical development program and further build out its retina pipeline.
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener